Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in XXXX by monitoring changes in clinical parameters and inflammatory markers in exhaled breath.

@entity6542 @entity1 @entity565 @entity842 @entity56
INTRODUCTION: The aim of this study was to evaluate the effectiveness of @entity6542 ( @entity6542 ) management with allergoids in @entity1 with @entity56 by monitoring changes in clinical parameters and inflammatory markers in exhaled breath. METHODS: The study population included 43 @entity1 (24 males) of 6-14 years of age, who had @entity56 and were sensitized to mites. Twenty-three individuals were treated with subcutaneous @entity6542 (PURETHAL   Mites, HAL Allergy) for 8 months, i.e. the @entity6542 group, and 20 were given medication to treat symptoms only, i.e. the control group. Before treatment and after 4 and 8 months, several clinical parameters, the levels of exhaled @entity842 and the pH of exhaled breath condensate (EBC) were determined. RESULTS: The @entity6542 group presented with an improvement in @entity565 classification, a reduction in maintenance drug therapy and improved scores on the quality-of-life questionnaire. These changes were not observed in the control group. Both groups presented significant decreases in EBC pH values at 4 and 8 months after treatment compared to at baseline. However, analysis of the variable 'ratio' showed an increase in the EBC pH values after 8 months of treatment in the @entity6542 group compared with the values at 4 months. CONCLUSIONS: @entity6542 with standardized mite extract reduces @entity565 symptoms in @entity1 . A decrease in EBC pH values was observed in both groups, although the @entity6542 group presented a tendency of recovered values after 8 months. Future studies of EBC pH monitoring in the longer term are needed to determine the effectiveness of this marker.    2014 S. Karger AG, Basel.
